Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction

Figure 1

Graft survival after 1, 5, and 10 years was 90.16%, 81.94%, and 80.36% in the alemtuzumab group versus 89.52%, 78.52%, and 52.66% for KTx recipients who received basiliximab; .